Evidence map›Paper›PMID 40416155›Full record

ArticleCureus2025

Shared Pathogenic Features Between Serotonin Receptor Antagonist-Associated Diabetic Ketosis and Ketosis-Prone Type 2 Diabetes: A Case Report.

Shumpei Nakanishi, Haruhiko Sato, Yoichi Oikawa, Kaori Ikebukuro, Akira Shimada

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shumpei NakanishiDepartment of Endocrinology and Diabetes, Saitama Medical University, Saitama, JPN.
Haruhiko SatoDepartment of Endocrinology and Diabetes, Saitama Medical University, Saitama, JPN.
Yoichi OikawaDepartment of Endocrinology and Diabetes, Saitama Medical University, Saitama, JPN.
Kaori IkebukuroDepartment of Internal Medicine, Tsurugashima Medical Clinic, Saitama, JPN.
Akira ShimadaDepartment of Endocrinology and Diabetes, Saitama Medical University, Saitama, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ketosis-prone type 2 diabetes (KPD) is characterized by male predominance, onset at a young age, obesity, and sudden onset of diabetic ketosis/ketoacidosis without precipitating factors, negative anti-islet autoantibodies, and β-cell function preservation after recovery from diabetic ketosis/ketoacidosis following temporal insulin therapy. However, its pathogenesis remains unknown. We encountered a 49-year-old obese man presenting with diabetic ketosis, i.e., ketonuria, plasma glucose 252 mg/dL, HbA1c 12.8%, without anti-islet autoantibodies, induced by dose escalation of quetiapine, a serotonin receptor antagonist. After discontinuing quetiapine and starting subcutaneous intensive insulin therapy, diabetic ketosis rapidly resolved. Following glycemic state stabilization, insulin therapy was discontinued on the 11

Indexed as

5-hydroxyindoleacetic aciddiabetic ketosis/ketoacidosisketosis-prone type 2 diabetesserotoninserotonin receptor antagonist

Identifiers

PMID40416155
PMCPMC12101042

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.